Efficacy and tolerability of initial antiretroviral therapy: a systematic review
- 28 January 2009
- journal article
- review article
- Published by Wolters Kluwer Health in AIDS
- Vol. 23 (3) , 343-353
Abstract
Successful antiretroviral therapy (ART) is largely attributed to the type of third drug. Guidelines recommend regimens without systematic review of all factors that might affect treatment success, such as study design, eligibility criteria and participant characteristics. Why patients cease ART has not been systematically studied. Systematic review of initial ART studies (64 randomized, 15 cohort). Group-based analysis was by weighted, forward, stepwise, linear regression. Treatment efficacy (undetectable plasma HIV viral load by intention-to-treat) and cessation for adverse events. Seven variables were independently associated with study groups reporting higher treatment success (mean 59%, r = 0.79): nonwhite race (P = 0.002), exclusion for low haemoglobin (P = 0.0006), lower CD4 cell count (P = 0.014), dosing relative to food (P = 0.001), dual-nucleoside backbone (favouring didanosine or tenofovir with emtricitabine or lamivudine; P = 0.002), nonnucleoside analogue or ritonavir-boosted protease inhibitor as the third drug (P < 0.0001), and shorter follow-up (P = 0.0004). Although the most common cause of treatment cessation (9.0%), adverse events were reported in only half of studies and were significantly more likely in studies that were phase 2 or 3, academia-sponsored and less than 36 months duration, and in older participants. Nausea was the only adverse event significantly associated with treatment success (r = -0.277). Multiple reasons influence initial ART success beyond the type of third drug and should be considered when designing and comparing studies. Most studies are too short and report insufficient adverse event data. Didanosine is an effective option for initial ART, with particular relevance to resource-limited settings. ART guideline development might benefit from systematic review.Keywords
This publication has 15 references indexed in Scilit:
- Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapyAIDS, 2007
- Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-scoreAIDS, 2007
- Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studiesAIDS, 2007
- British HIV Association (BHIVA) guidelines for the treatment of HIV‐infected adults with antiretroviral therapy (2006)HIV Medicine, 2006
- An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adultsAIDS, 2006
- Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analysesThe Lancet, 2006
- Treatment for Adult HIV InfectionJAMA, 2006
- Combination Antiretroviral Therapy and the Risk of Myocardial InfarctionNew England Journal of Medicine, 2003
- Investigating and dealing with publication and other biases in meta-analysisBMJ, 2001
- Adverse effects of antiretroviral therapyThe Lancet, 2000